🔴 GeneDx is trading 4.1% down today as post-earnings selloff continues on guidance cut and impairment

GeneDx is trading at $61.26 (4.1% down) as investors continue to digest weak first-quarter 2026 earnings, a revenue guidance cut, and a Fabric Genomics-related impairment charge.

• The stock remains under pressure from multiple securities class action lawsuits and valuation concerns following the sharp post-earnings selloff.
• Today’s decline appears to be a continuation of negative market sentiment rather than a fresh company-specific headline.